ANSWERS FULLY ANALYSED EDITION EXAM 100% CORRECTLY/VERIFIED ANSWERS WITH
SATISFACTION GUARANTEED SUCCESS LATEST UPDATE 2023/2024 5TH EDITION WOO ROBINSON
TEST BANK GRADED A+
Chapter931.93
An93Introduction93to93Pharmacogenetics
Multiple93Choice
Identify93the93choice93that93best93completes93the93statement93or93answers93the93question.
93 1.93Genetic93polymorphisms93account93for93differences93in93metabolism,93including:
93939393
1. Poor93metabolizers,93who93lack93a93working93enzyme
2. Intermediate93metabolizers,93who93have93one93working,93wild-
type93allele93and93one93mutant
3. Extensive93metabolizers,93with93two93normally93functioning93alleles
4. All93of93the93above
93 2.93 Up93to9321%93of93Asians93are93ultra-rapid932D693metabolizers,93leading93to:
93939393
1. A93need93to93monitor93drugs93metabolized93by932D693for93toxicity
2. Increased93dosages93needed93of93drugs93metabolized93by932D6,93such9
3as93the93selective93seroto93reuptake93inhibitors
3. Decreased93conversion93of93codeine93to93morphine93by93CYP932D6
4. The93need93for93lowered93dosages93of93drugs,93such93as93beta93blockers
93 3.93 Rifampin93is93a93nonspecific93CYP45093inducer93that93may:
93939393
1. Lead93to93toxic93levels93of93rifampin93and93must93be93monitored93closely
2. Cause93toxic93levels93of93drugs,93such93as93oral93contraceptives,93when93coadministere
d
3. Induce93the93metabolism93of93drugs,93such93as93oral93contraceptives,93leading93to93ther
apeutic
4. Cause93nonspecific93changes93in93drug93metabolism
93 4.93 Inhibition93of93P-glycoprotein93by93a93drug93such93as93quinidine93may93lead93to:
93939393
1. Decreased93therapeutic93levels93of93quinidine
2. Increased93therapeutic93levels93of93quinidine
3. Decreased93levels93of93a93coadministered93drug,93such93as93digoxin,93
that93requires93P-glycopr93absorption93and93elimination
4. Increased93levels93of93a93coadministered93drug,93such93as93digoxin,93t
hat93requires93P-glycopro93absorption93and93elimination
93
, 5.93Warfarin93resistance93may93be93seen93in93patients93with93VCORC193mutation,93leadin
93939393
g93to:
1. Toxic93levels93of93warfarin93building93up
2. Decreased93response93to93warfarin
3. Increased93risk93for93significant93drug93interactions93with93warfarin
4. Less93risk93of93drug93interactions93with93warfarin
93
6.93Genetic93testing93for93VCORC193mutation93to93assess93potent
93939393
ial93warfarin93resistance93is93required93prior93to93prescribing93warfarin.
1. True
2. False
93
7.93Pharmacogenetic93testing93is93required93by93the93U.S.93Food
93939393
93and93Drug93Administration93prior93to93prescribing:
1. Erythromycin
2. Digoxin
3. Cetuximab
, 4. Rifampin
93
8.93Carbamazepine93has93a93Black93Box93Warning93recommending9
93939393
3testing93for93the93HLA-
B*150293allele93in93patients93with93Asian93ancestry93prior93to93starting93the
rapy93due93to:
1. Decreased93effectiveness93of93carbamazepine93in93treating93seizures93in93Asian93patien
ts93wit
HLA-B*150293allele
2. Increased93risk93for93drug93interactions93in93Asian93patients93with93the93HLA-
B*150293allele
3. Increased93risk93for93Stevens-Johnson93syndrome93in93Asian93patients93with93HLA-
B*150293a
4. Patients93who93have93the93HLA-
B*150293allele93being93more93likely93to93have93a93resistance93to93carb
amazepine
93
939393939.93 A93genetic93variation93in93how93the93metabolite93of93the
93cancer93drug93irinotecan93SN-
3893is93inactivated93by93the93body93may93lead93to:
1. Decreased93effectiveness93of93irinotecan93in93the93treatment93of93cancer
2. Increased93adverse93drug93reactions,93such93as93neutropenia
3. Delayed93metabolism93of93the93prodrug93irinotecan93into93the93active93metabolite93SN-
38
4. Increased93concerns93for93irinotecan93being93carcinogenic
93 10.93 Patients93who93have93a93poor93metabolism93phenotype93will93have:
9393
1. Slowed93metabolism93of93a93prodrug93into93an93active93drug,93leading93to93accumulati
on93of93pr
2. Accumulation93of93inactive93metabolites93of93drugs
3. A93need93for93increased93dosages93of93medications
4. Increased93elimination93of93an93active93drug
93 11.93Ultra-rapid93metabolizers93of93drugs93may93have:
9393
1. To93have93dosages93of93drugs93adjusted93downward93to93prevent93drug93accumulation
2. Active93drug93rapidly93metabolized93into93inactive93metabolites,93lea
ding93to93potential93thera93failure
3. Increased93elimination93of93active,93nonmetabolized93drug
, 4. Slowed93metabolism93of93a93prodrug93into93an93active93drug,93leading93to93an93accumu
lation93of
93
12.93A93provider93may93consider93testing93for93CYP2D693variant
9393
s93prior93to93starting93tamoxifen93for93breast93cancer93to:
1. Ensure93the93patient93will93not93have93increased93adverse93drug93reactions93to93the93ta
moxifen
2. Identify93potential93drug-drug93interactions93that93may93occur93with93tamoxifen
3. Reduce93the93likelihood93of93therapeutic93failure93with93tamoxifen93treatment
4. Identify93poor93metabolizers93of93tamoxifen